1319PPost-hoc analysis of CLARINET phase III study to investigate the influence of diabetic status on progression-free survival (PFS) of patients with neuroendocrine tumours (NETs) treated with lanreotide (LAN) or placebo (PBO). (23rd October 2018) - Pusceddu, S; Vernieri, C; Di Maio, M; Prinzi, N; Torchio, M; Buzzoni, R; Truong-Thanh, X-M; Mazzaferro, V; de Braud, F G M